400,000 Shares in Relay Therapeutics, Inc. $RLAY Acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 400,000 shares of the company’s stock, valued at approximately $3,980,000.

A number of other large investors have also added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its holdings in Relay Therapeutics by 4.0% in the first quarter. Renaissance Technologies LLC now owns 673,599 shares of the company’s stock worth $6,702,000 after acquiring an additional 25,700 shares in the last quarter. Gabelli Funds LLC bought a new position in shares of Relay Therapeutics in the first quarter worth approximately $119,000. Arrowstreet Capital Limited Partnership purchased a new stake in Relay Therapeutics during the 1st quarter valued at $6,649,000. Sei Investments Co. raised its stake in shares of Relay Therapeutics by 41.0% in the first quarter. Sei Investments Co. now owns 36,130 shares of the company’s stock worth $359,000 after purchasing an additional 10,500 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Relay Therapeutics by 18.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,940,536 shares of the company’s stock valued at $29,248,000 after purchasing an additional 460,186 shares in the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Insiders Place Their Bets

In other Relay Therapeutics news, insider Peter Rahmer sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total value of $954,500.00. Following the completion of the transaction, the insider directly owned 225,857 shares in the company, valued at $4,311,610.13. This represents a 18.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Donald A. Bergstrom sold 8,660 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $18.71, for a total transaction of $162,028.60. Following the completion of the transaction, the insider directly owned 409,897 shares in the company, valued at $7,669,172.87. This trade represents a 2.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 426,127 shares of company stock worth $7,426,087 over the last quarter. Company insiders own 5.04% of the company’s stock.

Relay Therapeutics Stock Performance

Shares of RLAY stock opened at $18.44 on Friday. The stock has a fifty day simple moving average of $16.58 and a two-hundred day simple moving average of $12.70. The firm has a market capitalization of $3.53 billion, a PE ratio of -11.75 and a beta of 1.67. Relay Therapeutics, Inc. has a 52-week low of $3.03 and a 52-week high of $20.79.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.58 million. On average, sell-side analysts forecast that Relay Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on RLAY shares. Citigroup reiterated an “outperform” rating on shares of Relay Therapeutics in a report on Wednesday, May 20th. Barclays upped their target price on shares of Relay Therapeutics from $21.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen upgraded shares of Relay Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. HC Wainwright boosted their price objective on shares of Relay Therapeutics from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Finally, The Goldman Sachs Group increased their price objective on shares of Relay Therapeutics from $22.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.92.

Relay Therapeutics Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.